Mankind Pharma share price surged 2% after Morgan Stanley initiated coverage with an ‘Overweight’ rating and a Rs 2,500 target price, citing strong growth potential. The brokerage anticipates robust revenue and EPS growth driven by domestic business recovery and the BSV segment, favoring Mankind Pharma for its favorable risk-reward profile.